BLOG

OSE details novel immuno-oncology strategy targeting ‘don’t eat me’ signaling in cancer

OSE Immunotherapeutics is among the companies pursuing this signaling pathway, and it has unveiled preclinical data supporting a novel strategy for disrupting it.